title: Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas.
abstract: Primary cutaneous lymphomas have been successfully treated with interferons (IFNs), counterbalancing the T-helper 2 (Th2)-skewing state. We undertook a phase 1, open-label, dose-escalating trial of repeated intratumoral administration of TG1042 in patients with advanced primary cutaneous T-cell lymphomas (CTCLs) and multilesional cutaneous B-cell lymphomas (CBCLs). TG1042 is a third-generation, nonreplicating human adenovirus vector containing a human IFN-gamma cDNA insert. Nine patients (7 CTCL, 2 CBCL) were enrolled at the following TG1042 doses: 3 x 10(9), 3 x 10(10), and 3 x 10(11) total particles. Local clinical response was observed in 5 of 9 treated patients (3 patients with complete response [CR] and 2 patients with partial response [PR]). Out of these, 3 patients showed systemic CR with the clearance of other noninjected skin lesions. Clinical response lasted for a median of 3 months (range, 1-6 months). Adverse events were mostly of grades 1 and 2. Seven of 9 treated patients had a detectable TG1042-derived IFN-gamma message in injected lesions after the first treatment cycle. A TG1042-IFN-gamma message was also detectable after several treatment cycles. We demonstrate the induction of humoral immune response to lymphoma tumor-antigen se70-2 after treatment. Our study shows that intralesional injections of TG1042 are both safe and well tolerated.
authors.affiliation: Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, 8091 Zurich, Switzerland. reinhard.dummer@usz.ch
authors.forename: Reinhard
authors.initials: R
authors.lastname: Dummer
authors.forename: Jessica C
authors.initials: JC
authors.lastname: Hassel
authors.forename: Friederike
authors.initials: F
authors.lastname: Fellenberg
authors.forename: Stefan
authors.initials: S
authors.lastname: Eichmüller
authors.forename: Tanja
authors.initials: T
authors.lastname: Maier
authors.forename: Philippe
authors.initials: P
authors.lastname: Slos
authors.forename: Bruce
authors.initials: B
authors.lastname: Acres
authors.forename: Pascal
authors.initials: P
authors.lastname: Bleuzen
authors.forename: Vincent
authors.initials: V
authors.lastname: Bataille
authors.forename: Patrick
authors.initials: P
authors.lastname: Squiban
authors.forename: Günter
authors.initials: G
authors.lastname: Burg
authors.forename: Mirjana
authors.initials: M
authors.lastname: Urosevic
mesh_terms: D000256:Adenoviridae / Q000235:genetics* / Q000502:physiology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D015870:Gene Expression; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D007150:Immunohistochemistry; D007167:Immunotherapy / Q000379:methods*; D007371:Interferon-gamma / Q000009:adverse effects / Q000235:genetics* / Q000276:immunology*; D008223:Lymphoma / Q000235:genetics / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D012878:Skin Neoplasms / Q000235:genetics / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D012333:RNA, Messenger; D007371:Interferon-gamma